Pharma major Lupin Ltd announced the launch of its generic Ipratropium Bromide nasal spray in the US market, offering a cost-effective alternative for patients suffering from runny nose conditions. The company launched the nasal solution in two strengths: 0.03% and 0.06%, both bioequivalent to Boehringer Ingelheim Pharmaceuticals' branded Atrovent nasal spray.
Product Specifications and Indications
The Ipratropium Bromide nasal spray 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. The higher strength 0.06% formulation targets rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older.
Both generic formulations have demonstrated bioequivalence to their branded counterparts, ensuring comparable therapeutic efficacy and safety profiles for patients requiring treatment for various forms of rhinitis.
Market Opportunity
According to IQVIA MAT May 2025 data cited by Lupin, the Ipratropium Bromide nasal solution market, represented by Atrovent, generated estimated annual sales of USD 63 million in the US. This substantial market size underscores the commercial potential for Lupin's generic entry into this therapeutic segment.
Strategic Significance
The launch represents Lupin's continued expansion in the US generic pharmaceutical market, particularly in the respiratory care segment. By offering bioequivalent alternatives to established branded products, the company aims to provide healthcare providers and patients with more affordable treatment options while maintaining therapeutic effectiveness.
The introduction of these generic nasal sprays addresses the treatment needs of patients across different age groups, from children as young as 5 years old to adults, covering a broad spectrum of rhinitis conditions including allergic, nonallergic perennial, and seasonal variants.
